摘要:
The present invention discloses compounds of the formula ##STR1## any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R, R.sup.3, and R.sup.4 each have the meanings set forth in the specification.The compounds possess valuable pharmaceutical properties as dopamine reuptake inhibitors.
摘要:
The present invention discloses compounds of the formula ##STR1## any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R, R.sup.3, and R.sup.4 each have the meanings set forth in the specification.The compounds possess valuable pharmaceutical properties as dopamine reuptake inhibitors.
摘要:
The present invention discloses compounds of the formula ##STR1## any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R, R.sub.3, and R.sup.4 each have the meanings set forth in the specification.The compounds possess valuable pharmaceutical properties as dopamine reuptake inhibitors.
摘要:
The present invention discloses compounds of the formula ##STR1## any mixture thereof, or a pharmaceutically acceptable salt thereof; wherein R, R.sup.3, and R.sub.4 each have the meanings set forth in the specification.The compounds possess valuable pharmaceutical properties as dopamine reuptake inhibitors.
摘要:
A compound having the formula ##STR1## wherein X is O, SR.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently of each other are hydrogen, halogen, or CF.sub.3 ;R' is hydrogen or NO.sub.2 ; andfurther a method of treating a disorder or disease of a living animal body, including a human, which is responsive to opening of potassium channels, which comprises administering to a living animal body, including a human, in need thereof an effective amount of a compound as above.
摘要:
A method of treating a disease in a mammal, including a human, responsive to blockade of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.11, R.sup.12, R.sup.13, R.sup.14 and R.sup.15 independently of each other are hydrogen, CF.sub.3, NO.sub.2, NH.sub.2, OH, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy or phenyl; andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently of each other are hydrogen, halogen, CF.sub.3, C.sub.1-6 -alkyl, NO.sub.2, NH.sub.2, OH or C.sub.1-6 -alkoxy,and a method as above wherein 1-(4-methoxyphenyl)-indole is employed,and a method as above wherein depression, memory disorders, Alzheimers disease and diabetes 2 is treated,and further a method as above wherein the active ingredient is administered in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent.
摘要:
New oxadiazolyl imidazobenzodiazepine derivatives having the formula ##STR1## wherein R.sup.3 has the formula ##STR2## wherein R" is hydrogen, C.sub.1-6 alkyl C.sub.1-6 alkoxymethyl or C.sub.3-6 - cycloalkyl;R.sup.4 is hydrogen;R.sup.5 is C.sub.1-6 alkyl or R.sup.4 and R.sup.5 together form a 2-4 membered alkylene bridge; and R.sup.A is C.sub.1-6 alkyl, C.sub.1-6 alkoxy, or C.sub.1-3 trifluoroalkyl, pharmaceutical compositions thereof, and method of treating therewith, are disclosed.The compounds and pharmaceutical compositions are useful in the amelioration, mitigation, or elimination of central nervous system disorders related to benzodiazepine receptors and especially as anticonvulsants, anxiolytics, hypnotics, and nootropics.
摘要:
New .beta.-carboline-3-carboxylic acid esters have the general formula I: ##STR1## wherein R.sup.4, R.sup.5 and R.sup.6 have specified meanings. The new compounds exhibit surprising psychotropic properties.
摘要:
The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.21 and R.sup.22 each independently are alkyl; andR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.11, R.sup.12, R.sup.13, and R.sup.14 each independently are hydrogen, halogen, CF.sub.3, CN, or NO.sub.2.The compounds are useful as in vivo active glutamate antagonists.
摘要:
A compound having the formula ##STR1## wherein R.sup.1 is C.sub.1-6 -alkyl which may be branched or cyclic;R.sup.2 is C.sub.1-6 -alkyl which may be branched or cyclic; or wherein R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n --, wherein n is 3, 4, 5.and a method of treating disorders of a mammal, including a human, responsive to the blockade of glutamic and aspartic acid receptors, with the same.